173 related articles for article (PubMed ID: 16262900)
21. Aldehyde dehydrogenase 2 protects against oxidative stress associated with pulmonary arterial hypertension.
Xu T; Liu S; Ma T; Jia Z; Zhang Z; Wang A
Redox Biol; 2017 Apr; 11():286-296. PubMed ID: 28030785
[TBL] [Abstract][Full Text] [Related]
22. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
[TBL] [Abstract][Full Text] [Related]
23. Interferon regulatory factor 7 inhibits rat vascular smooth muscle cell proliferation and inflammation in monocrotaline-induced pulmonary hypertension.
Deng Y; Guo SL; Li JQ; Xie SS; Zhou YC; Wei B; Wang Q; Wang F
Life Sci; 2021 Jan; 264():118709. PubMed ID: 33152351
[TBL] [Abstract][Full Text] [Related]
24. Regulatory effects of Prohibitin 1 on proliferation and apoptosis of pulmonary arterial smooth muscle cells in monocrotaline-induced PAH rats.
Cao YY; Ba HX; Li Y; Tang SY; Luo ZQ; Li XH
Life Sci; 2020 Jun; 250():117548. PubMed ID: 32173312
[TBL] [Abstract][Full Text] [Related]
25. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.
Schermuly RT; Krupnik E; Tenor H; Schudt C; Weissmann N; Rose F; Grimminger F; Seeger W; Walmrath D; Ghofrani HA
Am J Respir Crit Care Med; 2001 Nov; 164(9):1694-700. PubMed ID: 11719312
[TBL] [Abstract][Full Text] [Related]
26. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension.
Paulin R; Meloche J; Jacob MH; Bisserier M; Courboulin A; Bonnet S
Am J Physiol Heart Circ Physiol; 2011 Nov; 301(5):H1798-809. PubMed ID: 21890685
[TBL] [Abstract][Full Text] [Related]
27. [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].
Li XL; Guan RJ; Xu QH; Wu ZY
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Mar; 39(3):247-53. PubMed ID: 21609531
[TBL] [Abstract][Full Text] [Related]
28. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
29. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
30. The Anti-Inflammatory Effects and Clinical Potential of Dexmedetomidine in Pulmonary Arterial Hypertension.
Yamaguchi Y; Hosokawa S; Haraguchi G; Kajikawa Y; Sakurai M; Ishii T; Ando N; Morio T; Doi S; Furukawa T
J Pharmacol Exp Ther; 2023 May; 385(2):88-94. PubMed ID: 36849413
[TBL] [Abstract][Full Text] [Related]
31. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of profilin, cofilin-2 and LIMK2 in cultured pulmonary artery smooth muscle cells and in pulmonary arteries of monocrotaline-treated rats.
Dai YP; Bongalon S; Tian H; Parks SD; Mutafova-Yambolieva VN; Yamboliev IA
Vascul Pharmacol; 2006 May; 44(5):275-82. PubMed ID: 16524786
[TBL] [Abstract][Full Text] [Related]
33. Grape seed proanthocyanidin reverses pulmonary vascular remodeling in monocrotaline-induced pulmonary arterial hypertension by down-regulating HSP70.
Chen F; Wang H; Yan J; Lai J; Cai S; Yuan L; Zheng S
Biomed Pharmacother; 2018 May; 101():123-128. PubMed ID: 29482057
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension.
Lan B; Hayama E; Kawaguchi N; Furutani Y; Nakanishi T
PLoS One; 2015; 10(1):e0117211. PubMed ID: 25629315
[TBL] [Abstract][Full Text] [Related]
35. Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats.
Zhai FG; Zhang XH; Wang HL
Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):850-6. PubMed ID: 19298536
[TBL] [Abstract][Full Text] [Related]
36. Benefit of combined therapy with nicorandil and colchicine in preventing monocrotaline-induced rat pulmonary arterial hypertension.
Lee FY; Lu HI; Zhen YY; Leu S; Chen YL; Tsai TH; Chung SY; Chua S; Sheu JJ; Hsu SY; Chang HW; Sun CK; Yip HK
Eur J Pharm Sci; 2013 Nov; 50(3-4):372-84. PubMed ID: 23954457
[TBL] [Abstract][Full Text] [Related]
37. Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-κB Signaling Pathway to Attenuate Vascular Remodeling.
Liu J; Fang G; Lan C; Qiu C; Yao L; Zhang Q; Hu J; Zhang Y; Yang Y; Zhang Y
Drug Des Devel Ther; 2024; 18():767-780. PubMed ID: 38495631
[TBL] [Abstract][Full Text] [Related]
38. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
39. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
Schermuly RT; Roehl A; Weissmann N; Ghofrani HA; Schudt C; Tenor H; Grimminger F; Seeger W; Walmrath D
J Pharmacol Exp Ther; 2000 Feb; 292(2):512-20. PubMed ID: 10640287
[TBL] [Abstract][Full Text] [Related]
40. Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension.
Yu X; Zhao X; Zhang J; Li Y; Sheng P; Ma C; Zhang L; Hao X; Zheng X; Xing Y; Qiao H; Qu L; Zhu D
Eur J Pharmacol; 2019 May; 850():97-108. PubMed ID: 30753867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
